Profund Advisors LLC Ultragenyx Pharmaceutical Inc. Transaction History

Profund Advisors LLC

  • $2.59 Billion
  • Q3 2024

A detailed history of Profund Advisors LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Profund Advisors LLC holds 18,613 shares of RARE stock, worth $814,318. This represents 0.04% of its overall portfolio holdings.

Number of Shares
18,613
Previous 22,401 16.91%
Holding current value
$814,318
Previous $920,000 12.28%
% of portfolio
0.04%
Previous 0.03%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$40.21 - $59.36 $152,315 - $224,855
-3,788 Reduced 16.91%
18,613 $1.03 Million
Q2 2024

Aug 13, 2024
SELL
$37.42 - $51.61 $190,205 - $262,333
-5,083 Reduced 18.49%
22,401 $920,000
Q1 2024

May 08, 2024
SELL
$43.02 - $53.69 $323,983 - $404,339
-7,531 Reduced 21.51%
27,484 $1.28 Million
Q4 2023

Feb 14, 2024
BUY
$31.73 - $49.19 $157,190 - $243,687
4,954 Added 16.48%
35,015 $1.67 Million
Q3 2023

Nov 13, 2023
BUY
$34.92 - $46.66 $47,316 - $63,224
1,355 Added 4.72%
30,061 $1.07 Million
Q2 2023

Aug 10, 2023
SELL
$37.35 - $52.15 $119,333 - $166,619
-3,195 Reduced 10.02%
28,706 $1.32 Million
Q1 2023

May 11, 2023
BUY
$36.99 - $48.71 $890,756 - $1.17 Million
24,081 Added 307.94%
31,901 $1.28 Million
Q4 2022

Feb 02, 2023
BUY
$33.72 - $46.33 $6,170 - $8,478
183 Added 2.4%
7,820 $362,000
Q3 2022

Nov 04, 2022
SELL
$39.96 - $66.14 $14,105 - $23,347
-353 Reduced 4.42%
7,637 $316,000
Q2 2022

Aug 01, 2022
SELL
$45.8 - $85.4 $22,945 - $42,785
-501 Reduced 5.9%
7,990 $477,000
Q1 2022

May 10, 2022
SELL
$62.2 - $84.4 $54,798 - $74,356
-881 Reduced 9.4%
8,491 $617,000
Q4 2021

Feb 08, 2022
SELL
$73.71 - $87.86 $119,999 - $143,036
-1,628 Reduced 14.8%
9,372 $788,000
Q3 2021

Nov 12, 2021
BUY
$77.92 - $102.4 $13,480 - $17,715
173 Added 1.6%
11,000 $992,000
Q2 2021

Aug 12, 2021
SELL
$92.19 - $115.71 $202,910 - $254,677
-2,201 Reduced 16.89%
10,827 $1.03 Million
Q1 2021

May 14, 2021
SELL
$106.9 - $167.73 $104,762 - $164,375
-980 Reduced 7.0%
13,028 $1.48 Million
Q4 2020

Feb 09, 2021
BUY
$84.4 - $177.39 $202,391 - $425,381
2,398 Added 20.65%
14,008 $1.94 Million
Q3 2020

Nov 13, 2020
SELL
$72.98 - $90.0 $129,685 - $159,930
-1,777 Reduced 13.27%
11,610 $954,000
Q2 2020

Aug 03, 2020
BUY
$46.91 - $78.22 $107,846 - $179,827
2,299 Added 20.73%
13,387 $1.05 Million
Q1 2020

May 15, 2020
SELL
$33.8 - $62.9 $155,175 - $288,773
-4,591 Reduced 29.28%
11,088 $493,000
Q4 2019

Feb 18, 2020
BUY
$36.08 - $45.83 $71,041 - $90,239
1,969 Added 14.36%
15,679 $670,000
Q3 2019

Nov 12, 2019
SELL
$42.5 - $63.11 $28,007 - $41,589
-659 Reduced 4.59%
13,710 $587,000
Q2 2019

Aug 13, 2019
SELL
$54.93 - $74.36 $56,248 - $76,144
-1,024 Reduced 6.65%
14,369 $912,000
Q1 2019

May 15, 2019
BUY
$39.87 - $69.36 $57,572 - $100,155
1,444 Added 10.35%
15,393 $1.07 Million
Q4 2018

Feb 14, 2019
SELL
$38.89 - $77.3 $132,264 - $262,897
-3,401 Reduced 19.6%
13,949 $607,000
Q3 2018

Nov 13, 2018
BUY
$71.81 - $90.15 $125,452 - $157,492
1,747 Added 11.2%
17,350 $1.32 Million
Q2 2018

Aug 13, 2018
SELL
$48.54 - $85.31 $50,967 - $89,575
-1,050 Reduced 6.31%
15,603 $1.2 Million
Q1 2018

May 14, 2018
BUY
$44.33 - $58.52 $39,409 - $52,024
889 Added 5.64%
16,653 $849,000
Q4 2017

Feb 14, 2018
SELL
$43.54 - $57.32 $73,539 - $96,813
-1,689 Reduced 9.68%
15,764 $731,000
Q3 2017

Nov 13, 2017
BUY
$49.79 - $66.32 $76,328 - $101,668
1,533 Added 9.63%
17,453 $930,000
Q2 2017

Aug 11, 2017
BUY
N/A
15,920
15,920 $989,000

Others Institutions Holding RARE

# of Institutions
325
Shares Held
85.6M
Call Options Held
520K
Put Options Held
406K
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.06B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email